U 87
Alternative Names: U-87Latest Information Update: 03 Oct 2024
At a glance
- Originator Shanghai Unicar-Therapy Bio-medicine Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Head and neck cancer; Pancreatic cancer
Most Recent Events
- 03 Oct 2024 NCT06614686: Intro, KDM and dev t updated, ROA was selected as parenteral assumed based on the given formulation
- 20 Sep 2024 Phase-I clinical trials in Head and neck cancer (Late-stage disease) in China (Parenteral) (NCT06614686)
- 19 Oct 2022 Phase-I clinical trials in Pancreatic cancer (In adults, In the elderly, Second-line therapy or greater, Late-stage disease) in China (Intratumoural) (NCT05605197)